PMID- 18343152
OWN - NLM
STAT- MEDLINE
DCOM- 20080916
LR  - 20211203
IS  - 1040-8428 (Print)
IS  - 1040-8428 (Linking)
VI  - 67
IP  - 1
DP  - 2008 Jul
TI  - Targeting AMPK: a new therapeutic opportunity in breast cancer.
PG  - 1-7
LID - 10.1016/j.critrevonc.2008.01.007 [doi]
AB  - BACKGROUND: This paper reviews the mammalian Target Of Rapamycin (mTOR) pathway 
      dysregulation in breast cancer, and the current evidence targeting this pathway 
      directly or through activation of AMP-activated protein kinase (AMPK) as an 
      additional therapeutic opportunity for intervention in breast cancer. METHODS: 
      Relevant articles were identified through computerised searches of Medline and 
      Pubmed. Secondary articles were identified from the reference lists of key papers 
      and by hand searching. RESULTS AND CONCLUSION: The current consensus to target 
      the AMPK/mTOR pathway in breast cancer is based on in vitro and epidemiological 
      evidences. A low incidence of cancer in diabetic patients on metformin has been 
      explained in vitro by the drug's anti-proliferative effect through activation of 
      AMPK. There is a need to explore the anticancer effects of metformin and the 
      potential to develop the therapeutic avenues offered by targeting the AMPK/mTOR 
      pathway.
FAU - Hadad, Sirwan M
AU  - Hadad SM
AD  - Department of Surgery and Molecular Oncology, Ninewells Hospital and Medical 
      School, Dundee, Scotland, United Kingdom. s.hadad@dundee.ac.uk
FAU - Fleming, Stewart
AU  - Fleming S
FAU - Thompson, Alastair M
AU  - Thompson AM
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PT  - Review
DEP - 20080314
PL  - Netherlands
TA  - Crit Rev Oncol Hematol
JT  - Critical reviews in oncology/hematology
JID - 8916049
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
RN  - EC 2.7.- (Protein Kinases)
RN  - EC 2.7.1.1 (MTOR protein, human)
RN  - EC 2.7.11.1 (TOR Serine-Threonine Kinases)
RN  - EC 2.7.11.3 (AMP-Activated Protein Kinase Kinases)
SB  - IM
MH  - AMP-Activated Protein Kinase Kinases
MH  - Animals
MH  - Breast Neoplasms/*enzymology
MH  - Female
MH  - Humans
MH  - Hypoglycemic Agents/pharmacology
MH  - Metformin/pharmacology
MH  - Protein Kinases/*metabolism
MH  - Signal Transduction/*physiology
MH  - TOR Serine-Threonine Kinases
RF  - 86
EDAT- 2008/03/18 09:00
MHDA- 2008/09/17 09:00
CRDT- 2008/03/18 09:00
PHST- 2007/09/06 00:00 [received]
PHST- 2008/01/15 00:00 [revised]
PHST- 2008/01/25 00:00 [accepted]
PHST- 2008/03/18 09:00 [pubmed]
PHST- 2008/09/17 09:00 [medline]
PHST- 2008/03/18 09:00 [entrez]
AID - S1040-8428(08)00019-X [pii]
AID - 10.1016/j.critrevonc.2008.01.007 [doi]
PST - ppublish
SO  - Crit Rev Oncol Hematol. 2008 Jul;67(1):1-7. doi: 
      10.1016/j.critrevonc.2008.01.007. Epub 2008 Mar 14.